EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Urinary Incontinence - Pipeline Review, H1 2017

  • ID: 4091114
  • Report
  • February 2017
  • 66 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Celogos SA
  • Cook MyoSite Inc
  • GTx Inc
  • Ipsen SA
  • Outpost Medicine Ltd
  • MORE
Urinary Incontinence - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Celogos SA
  • Cook MyoSite Inc
  • GTx Inc
  • Ipsen SA
  • Outpost Medicine Ltd
  • MORE
Introduction

Urinary Incontinence - Overview

Urinary Incontinence - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Celogos SA

Cook MyoSite Inc

FemmePharma Global Healthcare Inc

GTx Inc

Innovacell Biotechnologie AG

Ipsen SA

Outpost Medicine Ltd

Pfizer Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Ltd

Urinary Incontinence - Drug Profiles

(mirabegron + solifenacin succinate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abobotulinumtoxina - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enobosarm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gtx-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICES-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RCD-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Urinary Incontinence - Dormant Projects

Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones

Featured News & Press Releases

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting

Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence

Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence

May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg

Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference

Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency

Aug 30, 2011: Innovacell passes a further milestone

Feb 22, 2011: Innovacell makes further progress on product development

Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence

Oct 31, 2008: Fesoterodine Approved in the U.S

Feb 28, 2007: HRA Pharma Invest An Additional Euro 2.5 M In Cell Therapy Through Its Subsidiary Celogos

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Urinary Incontinence, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Urinary Incontinence - Pipeline by Astellas Pharma Inc, H1

Urinary Incontinence - Pipeline by Celogos SA, H1

Urinary Incontinence - Pipeline by Cook MyoSite Inc, H1

Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H1

Urinary Incontinence - Pipeline by GTx Inc, H1

Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1

Urinary Incontinence - Pipeline by Ipsen SA, H1

Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H1

Urinary Incontinence - Pipeline by Pfizer Inc, H1

Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H1

Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Urinary Incontinence - Dormant Projects, H1

Urinary Incontinence - Dormant Projects, H1 2017 (Contd..1), H1

Urinary Incontinence - Discontinued Products, H1

List of Figures:

Number of Products under Development for Urinary Incontinence, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Astellas Pharma Inc
  • Celogos SA
  • Cook MyoSite Inc
  • FemmePharma Global Healthcare Inc
  • GTx Inc
  • Innovacell Biotechnologie AG
  • Ipsen SA
  • Outpost Medicine Ltd
  • Pfizer Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Company Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll